| Name | Title | Contact Details |
|---|---|---|
Christopher McGorry |
Associate Director, R&D Financial and Stategic Planning | Profile |
Elizabeth Hetherman |
Director, R&D Finance & Accounting | Profile |
Bob Brown |
CSO, SVP Research and Development | Profile |
Brightstone specializes in creating a customized support program for young people needing help through mentoring. Brightstone uses an action oriented approach that creates learning opportunities through real life situations. Our participants move beyon...
Embecta will be the name of the independent, publicly-traded company that will hold BD`s Diabetes Care business
InnovoTex Inc. is a mid-stage pharmaceutical company developing the TEX Core portfolio of novel therapeutics capable of targeting multiple solid tumor indications.
Hysitron is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. Uncontrolled, progressive fibrosis leads to organ dysfunction and failure, and potentially death. In the U.S., many millions of Americans are afflicted with a fibrosis-related disease, which may affect organs including the kidney, liver, lungs, skin, and eye.